Background Riociguat, a member of a new class of compounds (soluble guanylate cyclase
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …

Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed
numerous and exciting developments in chronic thromboembolic pulmonary hypertension (…

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is a known
sequela of acute pulmonary embolic disease and yet remains underdiagnosed. Although …

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable
and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the …

Background Macitentan is beneficial for long-term treatment of pulmonary arterial
hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) …

Most patients with chronic thromboembolic pulmonary hypertension are operable, and
pulmonary endarterectomy is the treatment of choice. Pulmonary endarterectomy should not be …

Over the past 4 decades, chronic thromboembolic pulmonary hypertension has evolved from
an autopsy curiosity to a potentially correctable form of pulmonary hypertension. Advances …

New and emerging therapies might provide benefit in patients with pulmonary arterial
hypertension. Their efficacy and safety will be compared with existing combination therapies in …

Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating,
and life-threatening disease. We investigated associations between markers of disease …